Development and comparison of three 89 Zr-labeled anti-CLDN18.2 antibodies to noninvasively evaluate CLDN18.2 expression in gastric cancer: a preclinical study.

Guilan HuWenjia ZhuYu LiuYuan WangZheng ZhangShikun ZhuWenwen DuanPeipei ZhouChao FuFang LiLi Huo

Published in: European journal of nuclear medicine and molecular imaging (2022)

Zr-anti-CLDN18.2 VHH-ABD seems to be the optimal choice balancing tumor uptake and liver background. They can provide essential information to select patients who are likely to benefit from CLDN18.2-targeted treatment.

Keyphrases

pet imaging
end stage renal disease
ejection fraction
poor prognosis
chronic kidney disease
newly diagnosed
prognostic factors
healthcare
computed tomography
health information
mesenchymal stem cells
social media
combination therapy
bone marrow